Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for Reducing Drug Demand in Opioid Use Disorder
NCT05829655Phase 1Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Aug 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in opioid use disorder (OUD) comparing Suvorexant (20mg/day) with Placebo (2 arms). Primary endpoints: Demand Intensity, Demand Elasticity and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
suvorexant
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05829655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829655.